DGAP-News: CureVac : CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV
CureVac : CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV
DGAP-News: CureVac / Key word(s): Study CureVac : CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV 23.10.2020 / 13:15 The issuer is solely responsible for the content of this announcement. CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV - Strong induction of antibody and T cell responses in animal models - Protection of the lung, reduction of viral load in nose and throat in challenge studies - Favorable safety profile with no evidence of vaccine-enhanced disease
CVnCoV demonstrated dose-dependent activation of the humoral immune system in mice at doses of 0.25, 1 and 4µg. Strong IgG1 and IgG2a binding antibody titers were observed at all doses and translated efficiently into neutralizing antibodies that were detected even at the lowest dose. Neutralizing antibodies started to develop 3 weeks after the first vaccination and strongly increased after the second vaccination. The impact of different dosing schedules for the two-injection (prime and boost) regimen was investigated at 2µg with 1, 2, 3, or 4 weeks between the first and second vaccination. The data showed induction of IgG1 and IgG2a binding antibodies 7 days after the first vaccination. Titers increased after the second vaccination, showing higher response levels with longer injection intervals. Binding antibodies efficiently translated into neutralizing antibodies, which started to develop 4 weeks after the first vaccination and significantly increased after the second vaccination. Efficient induction of neutralizing antibodies was in line with favorable IgG2a/IgG1 ratios, indicating a balanced Th1/Th2 profile. There was no evidence of a Th2-biased immune response, indicating a low likelihood for vaccine-induced disease enhancement. "The preclinical data published today show that our COVID-19 vaccine candidate has the potential to induce an efficacious and balanced immune response, mimicking the natural immune defense and providing lung protection in a relevant challenge model," Dr. Mariola Fotin-Mleczek, Chief Technology Officer of CureVac, said. "The study adds to our understanding of CVnCoV, which is currently being evaluated in Phase 1 and 2a clinical trials." CVnCoV-vaccinated mice showed positive induction of multifunctional IFN(+/TFN+ CD4+ and CD8+ The potential protective efficiency of CVnCoV was demonstrated in hamsters, representing an established animal model to investigate human-relevant immunogenicity and pathogenesis. Vaccine dose of 10µg in hamsters showed very good reduction in replicating virus levels in the upper respiratory tract and complete lung protection in treated animals. Following viral challenge, lungs of vaccinated animals showed no evidence of disease enhancement. About CVnCoV About CureVac CureVac Media Contact CureVac Investor Relations Contact For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.
23.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
1142776 23.10.2020